Evaluation of intravitreal bevacizumab as monotherapy and in combination with macular grid laser photocoagulation in diffuse diabetic macular edema
BACKGROUND AND OBJECTIVE: The objective of the study was to compare the efficacy of intravitreal bevacizumab (IVB) as monotherapy versus combination with modified macular grid (MMG) laser photocoagulation in the primary treatment of diffuse diabetic macular edema (DDME). MATERIALS AND METHODS: A pro...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| Series: | Oman Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ojoonline.org/article.asp?issn=0974-620X;year=2018;volume=11;issue=3;spage=248;epage=253;aulast=Das |
| _version_ | 1831799235750658048 |
|---|---|
| author | Gopal K Das Pramod K Sahu Laura V L. Biakthangi Divya Jain |
| author_facet | Gopal K Das Pramod K Sahu Laura V L. Biakthangi Divya Jain |
| author_sort | Gopal K Das |
| collection | DOAJ |
| description | BACKGROUND AND OBJECTIVE: The objective of the study was to compare the efficacy of intravitreal bevacizumab (IVB) as monotherapy versus combination with modified macular grid (MMG) laser photocoagulation in the primary treatment of diffuse diabetic macular edema (DDME).
MATERIALS AND METHODS: A prospective randomized trial was carried out in sixty eyes with DDME after Institutional Ethical clearance. Group A received three doses of IVB at a 1-month interval. Group B received MMG in addition to IVB. Complete examination including best-corrected visual acuity (BCVA) (Snellen's), central macular thickness (CMT) using spectral domain-optical coherence tomography was carried out at 0, 1, 4, 8, 12, and 24 weeks.
RESULTS: mean CMT at baseline, 12 and 24 weeks in Group A was 401 (±76), 280 (±49), and 307 (±46) and in Group B, 405 (±73), 237 (±33), and 242 (±45), respectively. Group B had significantly greater reductions (P < 0.001) from 12 weeks onward. BCVA and contrast sensitivity showed improvements with no significant difference.
CONCLUSION: Combined therapy has more advantage in primary DDME by reducing CMT on longer follow-up. |
| first_indexed | 2024-12-22T17:42:41Z |
| format | Article |
| id | doaj.art-b4cf10d39b9c4f848d2a617cde69d586 |
| institution | Directory Open Access Journal |
| issn | 0974-620X |
| language | English |
| last_indexed | 2024-12-22T17:42:41Z |
| publishDate | 2018-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Oman Journal of Ophthalmology |
| spelling | doaj.art-b4cf10d39b9c4f848d2a617cde69d5862022-12-21T18:18:23ZengWolters Kluwer Medknow PublicationsOman Journal of Ophthalmology0974-620X2018-01-0111324825310.4103/ojo.OJO_196_2016Evaluation of intravitreal bevacizumab as monotherapy and in combination with macular grid laser photocoagulation in diffuse diabetic macular edemaGopal K DasPramod K SahuLaura V L. BiakthangiDivya JainBACKGROUND AND OBJECTIVE: The objective of the study was to compare the efficacy of intravitreal bevacizumab (IVB) as monotherapy versus combination with modified macular grid (MMG) laser photocoagulation in the primary treatment of diffuse diabetic macular edema (DDME). MATERIALS AND METHODS: A prospective randomized trial was carried out in sixty eyes with DDME after Institutional Ethical clearance. Group A received three doses of IVB at a 1-month interval. Group B received MMG in addition to IVB. Complete examination including best-corrected visual acuity (BCVA) (Snellen's), central macular thickness (CMT) using spectral domain-optical coherence tomography was carried out at 0, 1, 4, 8, 12, and 24 weeks. RESULTS: mean CMT at baseline, 12 and 24 weeks in Group A was 401 (±76), 280 (±49), and 307 (±46) and in Group B, 405 (±73), 237 (±33), and 242 (±45), respectively. Group B had significantly greater reductions (P < 0.001) from 12 weeks onward. BCVA and contrast sensitivity showed improvements with no significant difference. CONCLUSION: Combined therapy has more advantage in primary DDME by reducing CMT on longer follow-up.http://www.ojoonline.org/article.asp?issn=0974-620X;year=2018;volume=11;issue=3;spage=248;epage=253;aulast=DasAntivascular endothelial growth factorbevacizumabcentral macular thicknessdiabetes macular edemamacular grid laser photocoagulation |
| spellingShingle | Gopal K Das Pramod K Sahu Laura V L. Biakthangi Divya Jain Evaluation of intravitreal bevacizumab as monotherapy and in combination with macular grid laser photocoagulation in diffuse diabetic macular edema Oman Journal of Ophthalmology Antivascular endothelial growth factor bevacizumab central macular thickness diabetes macular edema macular grid laser photocoagulation |
| title | Evaluation of intravitreal bevacizumab as monotherapy and in combination with macular grid laser photocoagulation in diffuse diabetic macular edema |
| title_full | Evaluation of intravitreal bevacizumab as monotherapy and in combination with macular grid laser photocoagulation in diffuse diabetic macular edema |
| title_fullStr | Evaluation of intravitreal bevacizumab as monotherapy and in combination with macular grid laser photocoagulation in diffuse diabetic macular edema |
| title_full_unstemmed | Evaluation of intravitreal bevacizumab as monotherapy and in combination with macular grid laser photocoagulation in diffuse diabetic macular edema |
| title_short | Evaluation of intravitreal bevacizumab as monotherapy and in combination with macular grid laser photocoagulation in diffuse diabetic macular edema |
| title_sort | evaluation of intravitreal bevacizumab as monotherapy and in combination with macular grid laser photocoagulation in diffuse diabetic macular edema |
| topic | Antivascular endothelial growth factor bevacizumab central macular thickness diabetes macular edema macular grid laser photocoagulation |
| url | http://www.ojoonline.org/article.asp?issn=0974-620X;year=2018;volume=11;issue=3;spage=248;epage=253;aulast=Das |
| work_keys_str_mv | AT gopalkdas evaluationofintravitrealbevacizumabasmonotherapyandincombinationwithmaculargridlaserphotocoagulationindiffusediabeticmacularedema AT pramodksahu evaluationofintravitrealbevacizumabasmonotherapyandincombinationwithmaculargridlaserphotocoagulationindiffusediabeticmacularedema AT lauravlbiakthangi evaluationofintravitrealbevacizumabasmonotherapyandincombinationwithmaculargridlaserphotocoagulationindiffusediabeticmacularedema AT divyajain evaluationofintravitrealbevacizumabasmonotherapyandincombinationwithmaculargridlaserphotocoagulationindiffusediabeticmacularedema |